News

The suit is related to an abbreviated new drug application that Par filed with the FDA to market a generic version of DUEXIS tablets. The lawsuit claims infringement

The software, along with a patient portal, has been designed to better administer the clinical management of patient care and streamline internal reporting processes. Connexus provided Burman’s with

The Phase III randomized trial of farletuzumab is designed as a three-armed, double-blinded, controlled study. The study will evaluate farletuzumab at two different dosages in combination with second-line

OMONTYS is the once-monthly erythropoiesis-stimulating agent (ESA) for anemia. The approval was based on a new drug application, which included results from two Phase III studies. The studies

The research will combine expertise in data integration, informatics, genomics and imaging to identify subjects at risk of Alzheimer’s at an early disease stage. The study will be

FDA-approved Bionect is indicated for the management of irritation of the skin as well as first and second degree burns, and is currently being promoted and sold by

ADC Therapeutics was formed with an initial budget of $50m and 10 ADC development programs. The company’s plan will be to seek development and marketing partners after Phase

The $322,000 grant is a supplemental award to expand on promising initial research conducted by ACADIA under an earlier grant from MJFF. The new grant is intended to

Under the agreement, the companies will commercialise Ruconest (recombinant human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in the Republic of Korea. Ruconest